849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Aquocobalamin Breast Cancer	General Oncology, Inc.	P1	CC (43)
Arsonic Acid (As H3 O3) Breast Cancer	Sun Yat-sen University	P2	CC (43)
arx788 Breast Cancer	Fudan University	P2	CC (43)
Ast-301 Breast Cancer	Aston Sci. Inc.	P2	CC (43)
Atx-295 Breast Cancer	Accent Therapeutics	P1	CC (43)
Atx-559 Breast Cancer	Accent Therapeutics	P1	CC (43)
Avasopasem Breast Cancer	The University of Texas Health Science Center at San Antonio	P1	CC (43)
Benmelstobart Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CC (43)
Benzamide, 3-((3-Endo)-8-(2-((Cyclohexylmethyl)((2S)-2,3-Dihydroxy-1-Oxopropyl)Amino)Ethyl)-8-Azabicyclo(3.2.1)Oct-3-Yl)- Breast Cancer	HealthPartners Institute	P2	CC (43)
Bet Bromodomain Inhibitor Zen-3694 Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)
Biottt001 Breast Cancer	Beijing Bio-Targeting Therapeutics Technology Co., Ltd	P1	CC (43)
Carbomer Breast Cancer	The Netherlands Cancer Institute	P2	CC (43)
Cedazuridine Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)
Cephalexin Breast Cancer	Cairo University	P2	CC (43)
Clbr001 Breast Cancer	Calibr, a division of Scripps Research	P1	CC (43)
Clostridium Novyi-Nt Breast Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Culmerciclib Breast Cancer	Fudan University	P2	CC (43)
Cyclo Breast Cancer	The Netherlands Cancer Institute	P2	CC (43)
Dan-222 Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (43)
Desloratodine Breast Cancer	Montefiore Medical Center	P2	CC (43)
Deslorelin Breast Cancer	City of Hope Medical Center	P2	CC (43)
Doxycyclin Breast Cancer	Swiss Cancer Institute	P2	CC (43)
Doxycycline Breast Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Dupilumab Breast Cancer	Ottawa Hospital Research Institute	P2	CC (43)
Elimusertib Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)
Empagliflozin Breast Cancer	Hoffmann-La Roche	P1/2	CC (43)
ep0062 Breast Cancer	Ellipses Pharma	P1/2	CC (43)
Etx-636 Breast Cancer	Ensem Therapeutics	P1/2	CC (43)
FAPI74 Breast Cancer	Randy Yeh	P2	CC (43)
Fermented Wheat Germ Extract Breast Cancer	University of California, Davis	P1	CC (43)
Fianlimab Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (43)
Flibanserin Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (43)
fwd1802 Breast Cancer	Forward Pharmaceuticals Co., Ltd.	P1/2	CC (43)
Gotistobart Breast Cancer	OncoC4, Inc.	P1/2	CC (43)
Gsk 5733584 Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (43)
Hcq Breast Cancer	Abramson Cancer Center at Penn Medicine	P2	CC (43)
her3-dxd Breast Cancer	Daiichi Sankyo	P2	CC (43)
Herombopag Olamine Tablets Breast Cancer	Fujian Cancer Hospital	P2	CC (43)
Hrs-4508 Breast Cancer	Fudan University	P2	CC (43)
ibi354 Breast Cancer	Fudan University	P2	CC (43)
Irx 2 Breast Cancer	Providence Health & Services	P2	CC (43)
js207 Breast Cancer	Fudan University	P2	CC (43)
Jskn016 Breast Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P1/2	CC (43)
L-Ornithine L-Aspartate Breast Cancer	Fudan University	P2	CC (43)
Lucanisatuzumab Breast Cancer	Sun Yat-sen University	P2	CC (43)
Lunresertib Breast Cancer	Canadian Cancer Trials Group	P2	CC (43)
Menthol Breast Cancer	Necmettin Erbakan University	P2	CC (43)
Nbp Breast Cancer	Conjupro Biotherapeutics, Inc.	P2	CC (43)
nbq72s Breast Cancer	Nantong Bencao Quadriga Medical Technology Co. Ltd.	P2	CC (43)
N-Desmethyl-4-Hydroxytamoxifen Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (43)

Showing 451 to 500 of 849 assets

PreviousPage 10 of 17Next